Group 1 - The core point of the article is that Kingmed Diagnostics (SH 603882) announced the convening of its fourth board meeting on October 29, 2025, to review its Q3 2025 report [1] - For the year 2024, the revenue composition of Kingmed Diagnostics is 92.17% from third-party medical diagnostics and 7.83% from other businesses [1] - As of the report, Kingmed Diagnostics has a market capitalization of 13.4 billion yuan [1] Group 2 - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation [1] - A new "slow bull" market pattern is emerging, indicating a shift in market dynamics [1]

Core Viewpoint - The company, Kingmed Diagnostics (金域医学), reported a mixed performance in its Q3 2025 financial results, showing a decline in revenue but a significant improvement in net profit, indicating a gradual recovery in profitability despite industry challenges [1] Financial Performance - Q3 2025 revenue was 1.541 billion yuan, a year-on-year decrease of 11.32% - Net profit attributable to shareholders was 5.2 million yuan, a year-on-year increase of 24.08% - Non-recurring net profit attributable to shareholders was 14 million yuan, a year-on-year increase of 264.54% - For the first three quarters, the net profit attributable to shareholders was -80 million yuan, primarily due to a historical credit impairment loss of 345 million yuan [1] Cash Flow and Efficiency - The company's operating net cash flow showed a quarterly increase: 55 million yuan in Q1, 296 million yuan in Q2, and 321 million yuan in Q3, totaling 672 million yuan for the first three quarters - There was a notable improvement in accounts receivable collection [1] Strategic Initiatives - The company is focused on cost reduction, efficiency enhancement, and digital transformation, leading to a gradual increase in gross margin over the first three quarters - Kingmed Diagnostics emphasizes long-termism and innovation, implementing five strategic initiatives: upgrading marketing models, product mix strategies, differentiated services, cost leadership, and digital transformation [1] Market Development - The company has signed 21 community medical projects and won 14 new precision construction projects across various fields, including infection, oncology, genetics, and mass spectrometry - The revenue from the welfare system projects increased by 53.8% year-on-year [2] AI and Technology Integration - Kingmed Diagnostics has initiated the "AI IN ALL" program, advancing its smart medical testing capabilities - The company’s AI model, "Xiao Yu Yi," has been deployed in clinical settings, achieving over 5.99 million calls for smart report interpretations and 140,000 monthly active users [2] Data Trading and Collaboration - The company is the only medical institution selected as a pilot for the national trusted data space innovation development - It has registered six specialized disease datasets and listed 21 data products across various data exchanges, establishing long-term cooperation agreements with multiple stakeholders, including pharmaceutical companies and hospitals [3]

证券代码：603882 证券简称：金域医学 公告编号：2025-042 广州金域医学检验集团股份有限公司 第四届董事会第八次会议决议公告 一、董事会会议召开情况 广州金域医学检验集团股份有限公司（以下简称"公司"）第四届董事会第 八次会议于 2025 年 10 月 29 日以通讯方式召开，会议通知已于 2025 年 10 月 17 日以电子形式发出。会议由董事长梁耀铭先生主持，本次会议应出席董事 9 名， 实际出席董事 9 名。公司高级管理人员列席本次会议。会议召开符合《中华人民 共和国公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 出席本次会议的全体董事对本次会议的议案进行了认真审议，并以记名投票 表决方式通过以下决议： （一）审议通过《广州金域医学检验集团股份有限公司 2025 年第三季度报 告》 本议案经公司第四届董事会审计委员会 2025 年第四次会议审议通过，并同 意提交董事会审议。 经审议，董事会认为，公司依据相关法律、法规等规定编制的 2025 年第三 ...

证券代码：603882 证券简称：金域医学 公告编号：2025-045 二、减持计划的实施结果 广州金域医学检验集团股份有限公司 股东国创开元股权投资基金(有限合伙)减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、减持主体减持前基本情况 | 股东名称 | 国创开元股权投资基金(有限合伙) | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | √是 | □否 | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：/ | | | | 持股数量 | 30,880,905股 | | | 1 大股东持股的基本情况：本次减持计划实施前，国创开元为广州金域 医学检验集团股份有限公司（以下简称"公司"）持股 5%以上大股东， 持有公司 30,880,905 股，占公司总股本的 6.67%，上述股份均来源于 公司首次公开发行前取得的股份。 减持计划的实施结果情 ...

Financial Performance - The company's operating revenue for Q3 2025 was CNY 1,541,222,261.17, a decrease of 11.32% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2025 was CNY 5,197,288.53, an increase of 24.08% year-on-year[9] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2025 was CNY 13,713,114.88, a significant increase of 264.54% compared to the previous year[9] - For the first nine months of 2025, the company's operating revenue was CNY 4,538,151,376.33, down 19.23% year-on-year[4] - The net profit attributable to shareholders for the first nine months of 2025 decreased by 184.84% year-on-year[9] - The net profit for the first three quarters of 2025 was a loss of CNY 88,794,076.93, compared to a profit of CNY 83,867,861.65 in the same period of 2024[24] - The company reported a net loss attributable to the parent company of CNY 87.75 million for the current period, compared to a profit of CNY 90.79 million in the previous period, indicating a significant decline[25] - Basic and diluted earnings per share for the current period were both CNY -0.17, compared to CNY 0.20 in the same period of the previous year[25] Cash Flow and Assets - The company reported a net cash flow from operating activities of CNY 671,907,894.48 for the first nine months, an increase of 115.41%[5] - The company achieved a significant improvement in accounts receivable recovery during the reporting period, with a net cash flow from operating activities of CNY 321 million in Q3 2025[10] - Cash inflow from operating activities totaled CNY 4.97 billion, while cash outflow was CNY 4.30 billion, resulting in a net cash flow from operating activities of CNY 671.91 million[28] - The company reported a significant increase in tax refunds received, amounting to CNY 80.13 million compared to CNY 3.26 million in the previous year[28] - The cash and cash equivalents as of September 30, 2025, amounted to approximately CNY 2.44 billion, compared to CNY 2.43 billion at the end of 2024[17] - Cash and cash equivalents at the end of the period increased to CNY 2.43 billion from CNY 1.94 billion at the end of the previous year, reflecting a net increase of CNY 8.93 million[29] - The company's total assets decreased to CNY 9,713,905,810.84 in 2025 from CNY 10,391,893,742.49 in 2024, reflecting a decline of 6.5%[19] - Total liabilities decreased to CNY 2,760,133,718.04 in 2025 from CNY 2,916,821,149.44 in 2024, a reduction of 5.4%[19] - The company's total equity decreased to CNY 6,953,772,092.80 in 2025 from CNY 7,475,072,593.05 in 2024, a decline of 7.0%[20] Revenue and Costs - Total operating revenue for the first three quarters of 2025 was CNY 4,538,151,376.33, a decrease of 19.2% compared to CNY 5,618,852,446.76 in the same period of 2024[23] - Total operating costs for the first three quarters of 2025 were CNY 4,282,602,888.45, down 16.3% from CNY 5,117,588,587.38 in 2024[23] - Total revenue for the first three quarters of 2025 was approximately CNY 4.81 billion, a decrease from CNY 5.48 billion in the same period of 2024, representing a decline of about 12.1%[27] Research and Development - Research and development expenses for the first three quarters of 2025 were CNY 243,155,334.32, down 19.6% from CNY 302,366,808.51 in 2024[24] Investments and Projects - The company signed 21 new medical community projects in the first three quarters of 2025, responding to national policies for quality medical resource allocation[10] - The company's revenue from its welfare system projects increased by 53.8% year-on-year as of the end of Q3 2025, expanding the number of projects to 69[11] - The "Xiao Yu Yi" smart report interpretation tool was accessed over 5.99 million times, with a monthly active user count of 140,000 as of Q3 2025[11] - The company has registered 6 specialized disease datasets on the Guangdong data intellectual property registration platform and listed 21 data products across various data exchanges[11] Investment Income - The company reported an investment income of CNY 3,657,566.25 in 2025, compared to a loss of CNY 5,122,643.98 in 2024[24] Inventory and Cash Management - The company’s cash and cash equivalents decreased to CNY 1,086,694,814.42 in 2025 from CNY 1,255,918,382.21 in 2024, a decrease of 13.5%[19] - The company’s inventory decreased slightly to CNY 190,612,298.75 in 2025 from CNY 198,315,250.59 in 2024, a decline of 4.0%[19] Financing Activities - Investment activities resulted in a net cash outflow of CNY 262.78 million, compared to a net outflow of CNY 361.42 million in the same period of 2024, showing an improvement[28] - Financing activities led to a net cash outflow of CNY 393.74 million, an improvement from a net outflow of CNY 463.11 million in the previous year[29] - The company received CNY 113.75 million from borrowings in the current period, a decrease from CNY 285.65 million in the same period of 2024[29]

证券代码：603882 证券简称：金域医学 公告编号：2025-044 广州金域医学检验集团股份有限公司 （一）信用减值损失 根据《企业会计准则第 22 号——金融工具确认和计量》的规定，公司对以 摊余成本计量的金融资产，以预期信用损失为基础确认损失准备。公司依据信用 风险特征将应收账款、其他应收款等按账龄划分为若干组合，在组合基础上计算 预期信用损失，按账龄分析法计提减值。经测试，2025 年 1-9 月，公司计提信 1 关于计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、计提资产减值准备情况概述 为了客观、公允地反映广州金域医学检验集团股份有限公司（以下简称"公 司"）2025 年第三季度的财务状况以及经营成果，根据《企业会计准则》相关 规定和公司会计政策，公司对截至 2025 年 9 月 30 日的合并报表范围内各项资产 进行了减值测试，相应计提资产减值准备。详见下表： 单位：人民币元 | 类别 | 2025 年 1-9 月 | | --- | --- | | 一、信用减值损失 | 344,9 ...

重要内容提示： 本次日常关联交易事项无需经公司股东会审议。 广州金域医学检验集团股份有限公司 关于调整与金圻睿2025年度日常关联交易预计金额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603882 证券简称：金域医学 公告编号：2025-043 日常关联交易对上市公司的影响：公司及下属企业与关联人金圻睿的日 常关联交易为因日常经营活动所需而发生的正常业务往来，遵循公平、公正、公 开的原则，不会对公司的生产经营和财务状况产生重大影响，公司的主营业务也 不会因此而形成依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 广州金域医学检验集团股份有限公司（以下简称"公司"）于2025年1月13 日召开第四届董事会第三次会议，审议通过了《关于预计与广州市金圻睿生物科 技有限责任公司2025年度日常关联交易的议案》，具体内容详见公司于2025年1 月14日在上海证券交易所网站（www.sse.com.cn）及公司指定披露媒体《中国证 券报》、《上海证券报》、《证券日报》、《证券时报》刊登的《广州金域 ...

Core Insights - The deployment of the DeepGEM model by Guangzhou Kingmed Diagnostics Group aims to enhance cancer diagnosis through accurate and timely gene mutation predictions [1][2] - The collaboration involves Tencent and Guangzhou Medical University First Affiliated Hospital, focusing on developing a multimodal model for pathology and genetics [1][2] Group 1: DeepGEM Model Development - DeepGEM provides accurate predictions of gene mutations related to lung cancer, achieving a prediction accuracy of 78% to 99% within one minute [1] - The model addresses the challenges of conventional gene testing methods, which are often complex, time-consuming, and costly, particularly in resource-limited areas [1] Group 2: Clinical Application and Future Plans - Following successful validation, the three parties will promote the clinical application of DeepGEM for lung cancer gene mutation prediction [2] - There are plans to further develop a multimodal model that integrates various omics data, including pathology, proteomics, and metabolomics, for AI-assisted diagnosis across multiple cancer types [2] Group 3: Vision and Collaboration - The initiative aims to serve as a model for translating clinical research into practical applications, benefiting the public [2] - Kingmed Diagnostics expresses a desire to collaborate with more partners to create intelligent and accessible clinical diagnostic solutions [2]

Core Viewpoint - The company has successfully canceled its supervisory board and revised its articles of association, reflecting a significant governance change aimed at streamlining operations and enhancing decision-making efficiency [1][2]. Group 1: Corporate Governance Changes - The company held its second extraordinary general meeting of shareholders on September 9, 2025, where the proposal to cancel the supervisory board and amend the articles of association was approved [1]. - The company has completed the necessary business registration changes and filed the revised articles of association, receiving a new business license from the Guangzhou Market Supervision Administration [1]. Group 2: Company Information - The company is officially named Guangzhou Kingmed Diagnostics Group Co., Ltd., with a unified social credit code of 9144010178891443XK [1]. - The company is classified as a joint-stock company (listed, natural person investment or control) and is located at No. 10, Spiral Road, International Biological Island, Guangzhou [1]. - The registered capital of the company is 463,257,875 RMB, and it was established on May 26, 2006 [1]. - The company's business scope includes investment consulting, biotechnology development, software development, environmental monitoring, and various testing services [1].

Core Points - The company, Kingmed Diagnostics, announced the completion of business registration changes and the filing of its articles of association [2] - The company has obtained a new business license issued by the Guangzhou Market Supervision Administration [2]